The paradoxical role of IL-17 in atherosclerosis

Cellular Immunology

Volumn 297, Issue 1, 2015, Pages 33-39

  Gong, Fangchen ^a   Liu, Zhengxia ^a   Liu, Jingning ^a   Zhou, Ping ^a   Liu, Ying ^a   Lu, Xiang ^a  

^a THE SECOND AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Atherosclerosis; Coronary artery disease; IL 17; Immunity

Indexed keywords

BRODALUMAB; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 17; IXEKIZUMAB; IL17A PROTEIN, HUMAN;

ANIMAL MODEL; ATHEROPROTECTION; ATHEROSCLEROSIS; CD4+ T LYMPHOCYTE; CLINICAL RESEARCH; CLINICAL STUDY; CORONARY ARTERY DISEASE; CYTOKINE PRODUCTION; DRUG ACTIVITY; GAMMA DELTA T LYMPHOCYTE; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; TH17 CELL; ANIMAL; DISEASE MODEL; IMMUNOLOGY; INFLAMMATION; MOUSE; TH1 CELL; TH2 CELL;

ANIMALS; ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DISEASE MODELS, ANIMAL; HUMANS; INFLAMMATION; INTERLEUKIN-17; MICE; TH1 CELLS; TH17 CELLS; TH2 CELLS;

EID: 84940450615     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2015.05.007     Document Type: Review

References (79)

1. Ross R. Mechanisms of disease - atherosclerosis - an inflammatory disease. N. Engl. J. Med. 1999, 340:115-126.
2. van den Elzen S.G.P., León L., Brigl M., Leadbetter E.A., Gumperz J.E., Dascher C.C., Cheng T.Y., Sacks P.A.I.F.M., Besra G.S., Kent S.C., Moody D.B., Brenner M.B. Apolipoprotein mediated, p.o.l.a. presentation, apolipoprotein mediated pathways of lipid antigen presentation. Nature 2005, 437:906-910.
3. Hansson G.K., Hermansson A. The immune system in atherosclerosis. Nat. Immunol. 2011, 12:204-212.
4. McMahon M., Grossman J., FitzGerald J., Dahlin-Lee E., Wallace D.J., Thong B.Y., Badsha H., Kalunian K., Charles C., Navab M., Fogelman A.M., Hahn B.H. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum. 2006, 54:2541-2549.
5. Van Doornum S., McColl G., Wicks I.P. Accelerated atherosclerosis - an extraarticular feature of rheumatoid arthritis?. Arthritis Rheum. 2002, 46:862-873.
6. Mehta N.N., Azfar R.S., Shin D.B., Neimanns A.L., Troxel A.B., Gelfand J.M. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur. Heart J. 2010, 31:1000-1006.
7. Jonasson L., Holm J., Skalli O., Bondjers G., Hansson G.K. Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis (Dallas, Tex.) 1986, 6:131-138.
8. Kleindienst R., Xu Q., Willeit J., Waldenberger F.R., Weimann S., Wick G. Immunology of atherosclerosis. Demonstration of heat shock protein 60 expression and T lymphocytes bearing alpha/beta or gamma/delta receptor in human atherosclerotic lesions. Am. J. Pathol. 1993, 142:1927-1937.
9. Millonig G., Malcom G.T., Wick G. Early inflammatory-immunological lesions in juvenile atherosclerosis from the Pathobiological Determinants of Atherosclerosis in Youth (PDAY)-study. Atherosclerosis 2002, 160:441-448.
10. Gaffen S.L. Structure and signalling in the IL-17 receptor family. Nat. Rev. Immunol. 2009, 9:556-567.
11. Wright J.F., Guo Y., Quazi A., Luxenberg D.P., Bennett F., Ross J.F., Qiu Y., Whitters M.J., Tomkinson K.N., Dunussi-Joannopoulos K., Carreno B.M., Collins M., Wolfman N.M. Identification of an interleukin 17F/17A heterodimer in activated human CD4+T cells. J. Biol. Chem. 2007, 282:13447-13455.
12. de Boer O.J., van der Meer J.J., Teeling P., van der Loos C.M., Idu M.M., van Maldegem F., Aten J., van der Wal A.C. Differential expression of interleukin-17 family cytokines in intact and complicated human atherosclerotic plaques. J. Pathol. 2009.
13. Erbel C., Dengler T.J., Wangler S., Lasitschka F., Bea F., Wambsganss N., Hakimi M., Böckler D., Katus H.A., Gleissner C.A. Expression of IL-17A in human atherosclerotic lesions is associated with increased inflammation and plaque vulnerability. Basic Res. Cardiol. 2010, 106:125-134.
14. Fort M.M., Cheung J., Yen D., Li J., Zurawski S.M., Lo S., Menon S., Clifford T., Hunte B., Lesley R., Muchamuel T., Hurst S.D., Zurawski G., Leach M.W., Gorman D.M., Rennick D.M. IL-25 induces IL-4 IL-5, and IL-13 and Th2-associated pathologies in vivo. Immunity 2001, 15:985-995.
15. Toy D., Kugler D., Wolfson M., Vanden Bos T., Gurgel J., Derry J., Tocker J., Peschon J. Cutting edge: interleukin 17 signals through a heteromeric receptor complex. Journal of immunology 2006, 177:36-39.
16. Galkina E., Ley K. Immune and inflammatory mechanisms of atherosclerosis. Annu. Rev. Immunol. 2009, 165-197. Annual Reviews, Palo Alto.
17. Zhou X., Stemme S., Hansson G.K. Evidence for a local immune response in atherosclerosis. CD4+ T cells infiltrate lesions of apolipoprotein-E-deficient mice. Am. J. Pathol. 1996, 149:359-366.
18. Davenport P., Tipping P.G. The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice. Am. J. Pathol. 2003, 163:1117-1125.
19. Binder C.J., Hartvigsen K., Chang M.K., Miller M., Broide D., Palinski W., Curtiss L.K., Corr M., Witztum J.L. IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis. J. Clin. Invest. 2004, 114:427-437.
20. Liew F.Y., Pitman N.I., McInnes I.B. Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat. Rev. Immunol. 2010, 10:103-110.
21. Spits H., Artis D., Colonna M., Diefenbach A., Di Santo J.P., Eberl G., Koyasu S., Locksley R.M., McKenzie A.N.J., Mebius R.E., Powrie F., Vivier E. Innate lymphoid cells - a proposal for uniform nomenclature. Nat. Rev. Immunol. 2013, 13:145-149.
22. Ait-Oufella H., Sage A.P., Mallat Z., Tedgui A. Adaptive (T and B cells) immunity and control by dendritic cells in atherosclerosis. Circ. Res. 2014, 114:1640-1660.
23. Mor A., Planer D., Luboshits G., Afek A., Metzger S., Chajek-Shaul T., Keren G., George J. Role of naturally occurring CD4(+) CD25(+) regulatory T cells in experimental atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2007, 27:893-900.
24. Bettelli E., Korn T., Kuchroo V.K. Th17: the third member of the effector T cell trilogy. Curr. Opin. Immunol. 2007, 19:652-657.
25. Littman D.R., Rudensky A.Y. Th17 and regulatory T cells in mediating and restraining inflammation. Cell 2010, 140:845-858.
26. Lim H., Kim Y.U., Sun H., Lee J.H., Reynolds J.M., Hanabuchi S., Wu H.Z., Teng B.B., Chung Y. Proatherogenic Conditions Promote Autoimmune T Helper 17 Cell Responses In Vivo. Immunity 2014, 40:153-165.
27. Almanzar G., Oelinger R., Leuenberger J., Onestingel E., Rantner B., Zehm S., Cardini B., van der Zee R., Grundtman C., Wick G. Autoreactive HSP60 epitope-specific T-cells in early human atherosclerotic lesions. J. Autoimmun. 2012, 39:441-450.
28. Marks B.R., Nowyhed H.N., Choi J.-Y., Poholek A.C., Odegard J.M., Flavell R.A., Craft J. Thymic self-reactivity selects natural interleukin 17-producing T cells that can regulate peripheral inflammation. Nat. Immunol. 2009, 10. 1125-U1108.
29. Zhou L., Lopes J.E., Chong M.M.W., Ivanov I.I., Min R., Victora G.D., Shen Y., Du J., Rubtsov Y.P., Rudensky A.Y., Ziegler S.F., Littman D.R. TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing ROR gamma t function. Nature 2008, 453. 236-U214.
30. Korn T., Bettelli E., Gao W., Awasthi A., Jaeger A., Strom T.B., Oukka M., Kuchroo V.K. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 2007, 448. 484-U489.
31. Zhou L., Ivanov I.I., Spolski R., Min R., Shenderov K., Egawa T., Levy D.E., Leonard W.J., Littman D.R. IL-6 programs TH-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat. Immunol. 2007, 8:967-974.
32. Ghoreschi K., Laurence A., Yang X.-P., Tato C.M., McGeachy M.J., Konkel J.E., Ramos H.L., Wei L., Davidson T.S., Bouladoux N., Grainger J.R., Chen Q., Kanno Y., Watford W.T., Sun H.-W., Eberl G., Shevach E., Belkaid Y., Cua D.J., Chen W., O'Shea J.J. Generation of pathogenic T(H)17 cells in the absence of TGF-beta signalling. Nature 2010, 467. 967-U144.
33. Acosta-Rodriguez E.V., Napolitani G., Lanzavecchia A., Sallusto F. Interleukins 1 beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat. Immunol. 2007, 8:942-949.
34. Lee Y., Awasthi A., Yosef N., Quintana F.J., Xiao S., Peters A., Wu C., Kleinewietfeld M., Kunder S., Hafler D.A., Sobel R.A., Regev A., Kuchroo V.K. Induction and molecular signature of pathogenic T(H)17 cells. Nat. Immunol. 2012, 13:991-999.
35. Wick G., Jakic B., Buszko M., Wick M.C., Grundtman C. The role of heat shock proteins in atherosclerosis. Nat. Rev. Cardiol. 2014, 11:516-529.
36. Zuniga L.A., Jain R., Haines C., Cua D.J. Th17 cell development: from the cradle to the grave. Immunol. Rev. 2013, 252:78-88.
37. Zhang F.P., Meng G.X., Strober W. Interactions among the transcription factors Runx1, ROR gamma t and Foxp3 regulate the differentiation of interleukin 17-producing T cells. Nat. Immunol. 2008, 9:1297-1306.
38. Ivanov I.I., McKenzie B.S., Zhou L., Tadokoro C.E., Lepelley A., Lafaille J.J., Cua D.J., Littman D.R. The orphan nuclear receptor ROR gamma t directs the differentiation program of proinflammatory IL-17(+) T helper cells. Cell 2006, 126:1121-1133.
39. Holtmeier W., Kabelitz D. Gammadelta T cells link innate and adaptive immune responses. Chem. Immunol. Allergy 2005, 86:151-183.
40. Girardi M. Immunosurveillance and immunoregulation by gamma delta T cells. J. Invest. Dermatol. 2006, 126:25-31.
41. Martin B., Hirota K., Cua D.J., Stockinger B., Veldhoen M. Interleukin-17-producing gamma delta T cells selectively expand in response to pathogen products and environmental signals. Immunity 2009, 31:321-330.
42. Sutton C.E., Lalor S.J., Sweeney C.M., Brereton C.F., Lavelle E.C., Mills K.H.G. Interleukin-1 and IL-23 induce innate IL-17 production from gamma delta T cells, amplifying Th17 responses and autoimmunity. Immunity 2009, 31:331-341.
43. Sutton C.E., Mielke L.A., Mills K.H.G. IL-17-producing gamma delta T cells and innate lymphoid cells. Eur. J. Immunol. 2012, 42:2221-2231.
44. Hamada S., Umemura M., Shiono T., Tanaka K., Yahagi A., Begum M.D., Oshiro K., Okamoto Y., Watanabe H., Kawakami K., Roark C., Born W.K., O'Brien R., Ikuta K., Ishikawa H., Nakae S., Iwakura Y., Ohta T., Matsuzaki G. IL-17A produced by gamma delta T cells plays a critical role in innate immunity against Listeria monocytogenes infection in the liver. J. Immunol. 2008, 181:3456-3463.
45. Umemura M., Yahagi A., Hamada S., Begum M.D., Watanabe H., Kawakami K., Suda T., Sudo K., Nakae S., Iwakura Y., Matsuzaki G. IL-17-mediated regulation of innate and acquired immune response against pulmonary Mycobacterium bovis bacille Calmette-Guerin infection. J. Immunol. 2007, 178:3786-3796.
46. Liao Y.H., Xia N., Zhou S.F., Tang T.T., Yan X.X., Lv B.J., Nie S.F., Wang J., Iwakura Y., Xiao H., Yuan J., Jevallee H., Wei F., Shi G.P., Cheng X. Interleukin-17A contributes to myocardial ischemia/reperfusion injury by regulating cardiomyocyte apoptosis and neutrophil infiltration. J. Am. Coll. Cardiol. 2012, 59:420-429.
47. Uldrich A.P., Le Nours J., Pellicci D.G., Gherardin N.A., McPherson K.G., Lim R.T., Patel O., Beddoe T., Gras S., Rossjohn J., Godfrey D.I. CD1d-lipid antigen recognition by the gamma delta TCR. Nat. Immunol. 2013, 14. 1137-U1125.
48. Lutgens E., Vu D.M., Tai A., Tatro J.B., Karas R.H., Huber B.T., Beasley D. ΓδT cells are prevalent in the proximal aorta and drive nascent atherosclerotic lesion progression and neutrophilia in hypercholesterolemic mice. PLoS One 2014, 9:e109416.
49. de Boer O.J., Li X.F., Teeling P., Mackaay C., Ploegmakers H.J., van der Loos C.M., Daemen M.J., de Winter R.J., van der Wal A.C. Neutrophils, neutrophil extracellular traps and interleukin-17 associate with the organisation of thrombi in acute myocardial infarction. Thromb. Haemost. 2013, 109:290-297.
50. van Bruggen N., Ouyang W. Th17 cells at the crossroads of autoimmunity, inflammation, and atherosclerosis. Immunity 2014, 40:10-12.
51. Hansson G.K. Mechanisms of disease - inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 2005, 352:1685-1695.
52. Bonetti P.O., Lerman L.O., Lerman A. Endothelial dysfunction - a marker of atherosclerotic risk. Arterioscler. Thromb. Vasc. Biol. 2003, 23:168-175.
53. Patel D.N., King C.A., Bailey S.R., Holt J.W., Venkatachalam K., Agrawal A., Valente A.J., Chandrasekar B. Interleukin-17 stimulates C-reactive protein expression in hepatocytes and smooth muscle cells via p38 MAPK and ERK1/2-dependent NF-B and C/EBPbeta Activation. J. Biol. Chem. 2007, 282:27229-27238.
54. Iwakura Y., Nakae S., Saijo S., Ishigame H. The roles of IL-17A in inflammatory immune responses and host defense against pathogens. Immunol. Rev. 2008, 226:57-79.
55. Erbel C., Chen L., Bea F., Wangler S., Celik S., Lasitschka F., Wang Y., Bockler D., Katus H.A., Dengler T.J. Inhibition of IL-17A attenuates atherosclerotic lesion development in ApoE-deficient mice. J. Immunol. 2009, 183:8167-8175.
56. Smith E., Prasad K.M.R., Butcher M., Dobrian A., Kolls J.K., Ley K., Galkina E. Blockade of interleukin-17A results in reduced atherosclerosis in apolipoprotein E-deficient mice. Circulation 2010, 121:1746-1755.
57. Ng H.P., Burris R.L., Nagarajan S. Attenuated atherosclerotic lesions in apoE-Fc-chain-deficient hyperlipidemic mouse model is associated with inhibition of Th17 Cells and promotion of regulatory T cells. J. Immunol. 2011, 187:6082-6093.
58. Hot A., Lenief V., Miossec P. Combination of IL-17 and TNF alpha induces a pro-inflammatory, pro-coagulant and pro-thrombotic phenotype in human endothelial cells. Ann. Rheum. Dis. 2012, 71:768-776.
59. Cortez D.M., Feldman M.D., Mummidi S., Valente A.J., Steffensen B., Vincenti M., Barnes J.L., Chandrasekar B. IL-17 stimulates MMP-1 expression in primary human cardiac fibroblasts via p38 MAPK- and ERK1/2-dependent C/EBP-beta, NF-kappa B, and AP-1 activation. Am. J. Physiol.-Heart Circul. Physiol. 2007, 293:H3356-H3365.
60. Eid R.E., Rao D.A., Zhou J., Lo S.F.L., Ranjbaran H., Gallo A., Sokol S.I., Pfau S., Pober J.S., Tellides G. Interleukin-17 and interferon- are produced concomitantly by human coronary artery-infiltrating T cells and act synergistically on vascular smooth muscle cells. Circulation 2009, 119:1424-1432.
61. Zhu F., Wang Q., Guo C., Wang X., Cao X., Shi Y., Gao F., Ma C., Zhang L. IL-17 induces apoptosis of vascular endothelial cells - a potential mechanism for human acute coronary syndrome. Clin. Immunol. 2011, 141:152-160.
62. Cheng X., Taleb S., Wang J., Tang T.-T., Chen J., Gao X.-L., Yao R., Xie J.-J., Yu X., Xia N., Yan X.-X., Nie S.-F., Liao M.-Y., Cheng Y., Mallat Z., Liao Y.-H. Inhibition of IL-17A in atherosclerosis. Atherosclerosis 2011, 215:471-474.
63. Lee J., Baldwin W.M., Lee C.-Y., Desiderio S. Stat3β mitigates development of atherosclerosis in apolipoprotein E-deficient mice. J. Mol. Med. 2013, 91:965-976.
64. Cheng X., Yu X., Ding Y.J., Fu Q.Q., Xie J.J., Tang T.T., Yao R., Chen Y., Liao Y.H. The Th17/Treg imbalance in patients with acute coronary syndrome. Clinical immunology 2008, 127:89-97.
65. Potekhina A.V., Pylaeva E., Provatorov S., Ruleva N., Masenko V., Noeva E., Krasnikova T., Arefieva T. Treg/Th17 balance in stable CAD patients with different stages of coronary atherosclerosis. Atherosclerosis 2015, 238:17-21.
66. + Treg cell frequency in the peripheral circulation of patients with carotid artery plaques. Inflam. Res.: Off. J. Eur. Histamine Res. Soc. 2012, 61:1155-1165.
67. Frasch M.G., Ma Y., Yuan X., Deng L., Xu W., Zheng Y., Yue C., Zhang G., Xie F., Yang Y.H., Gantier M.P., Liu J., Xu D., Shen L. Imbalanced frequencies of Th17 and Treg cells in acute coronary syndromes are mediated by IL-6-STAT3 signaling. PLoS One 2013, 8:e72804.
68. Patel S., Chung S.H., White G., Bao S., Celermajer D.S. The "atheroprotective" mediators apolipoproteinA-I and Foxp3 are over-abundant in unstable carotid plaques. Int. J. Cardiol. 2010, 145:183-187.
69. Gistera A., Robertson A.-K.L., Andersson J., Ketelhuth D.F.J., Ovchinnikova O., Nilsson S.K., Lundberg A.M., Li M.O., Flavell R.A., Hansson G.K. Transforming growth factor-beta signaling in T cells promotes stabilization of atherosclerotic plaques through an interleukin-17-dependent pathway. Sci. Transl. Med. 2013, 5:196ra100.
70. Danzaki K., et al. Interleukin-17A deficiency accelerates unstable atherosclerotic plaque formation in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 2012, 32(2):273-280.
71. Taleb S., Romain M., Ramkhelawon B., Uyttenhove C., Pasterkamp G., Herbin O., Esposito B., Perez N., Yasukawa H., Van Snick J., Yoshimura A., Tedgui A., Mallat Z. Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis. J. Exp. Med. 2009, 206:2067-2077.
72. Simon T., Taleb S., Danchin N., Laurans L., Rousseau B., Cattan S., Montely J.M., Dubourg O., Tedgui A., Kotti S., Mallat Z. Circulating levels of interleukin-17 and cardiovascular outcomes in patients with acute myocardial infarction. Eur. Heart J. 2012, 34:570-577.
73. Ridker P.M., Danielson E., Fonseca F.A.H., Genest J., Gotto A.M., Kastelein J.J.P., Koenig W., Libby P., Lorenzatti A.J., MacFadyen J.G., Nordestgaard B.G., Shepherd J., Willerson J.T., Glynn R.J., Grp J.T.S. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009, 373:1175-1182.
74. Nissen S.E., Tuzcu E.M., Schoenhagen P., Crowe T., Sasiela W.J., Tsai J., Orazem J., Magorien R.D., O'Shaughnessy C., Ganz P., Investigators R. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N. Engl. J. Med. 2005, 352:29-38.
75. Hot A., Lavocat F., Lenief V., Miossec P. Simvastatin inhibits the pro-inflammatory and pro-thrombotic effects of IL-17 and TNF-alpha on endothelial cells. Ann. Rheum. Dis. 2013, 72:754-760.
76. Liu Z., et al. Treatment with telmisartan/rosuvastatin combination has a beneficial synergistic effect on ameliorating Th17/Treg functional imbalance in hypertensive patients with carotid atherosclerosis. Atherosclerosis 2014, 233(1):291-299.
77. Genovese M.C., Greenwald M.W., Cho C.S., Berman A., Jin L., Cameron G., Xie L., Braun D., Banerjee S., Warner L. A phase 2 study of multiple subcutaneous doses of LY2439821, An anti-IL-17 monoclonal antibody, patients with rheumatoid arthritis in two populations: naive to biologic therapy or inadequate responders to tumor necrosis factor alpha inhibitors. Arthritis Rheumat. 2011, 63:S1017.
78. Busse W.W., Holgate S., Kerwin E., Chon Y., Feng J., Lin J., Lin S.-L. Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, moderate to severe asthma. Am. J. Resp. Crit. Care Med. 2013, 188:1294-1302.
79. Madhur M.S., Funt S.A., Li L., Vinh A., Chen W., Lob H.E., Iwakura Y., Blinder Y., Rahman A., Quyyumi A.A., Harrison D.G. Role of interleukin 17 in inflammation, atherosclerosis, and vascular function in apolipoprotein e-deficient mice. Arterioscler. Thromb. Vasc. Biol. 2011, 31:1565-1572.